BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mössner J. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413-421. [PMID: 15298635 DOI: 10.1111/j.1365-2036.2004.02085.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yuan Y, Hunt RH. Evolving issues in the management of reflux disease?: . Current Opinion in Gastroenterology 2009;25:342-51. [DOI: 10.1097/mog.0b013e32832c1504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Talley NJ, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006;24:371-6. [DOI: 10.1111/j.1365-2036.2006.02983.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
3 Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. Prz Gastroenterol. 2018;13:6-15. [PMID: 29657605 DOI: 10.5114/pg.2018.74556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Labenz J, Morgner-miehlke A. An update on the available treatments for non-erosive reflux disease. Expert Opinion on Pharmacotherapy 2005;7:47-56. [DOI: 10.1517/14656566.7.1.47] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Junghard O, Halling K. Responsiveness of measures of heartburn improvement in non-erosive reflux disease. Health Qual Life Outcomes 2007;5:32. [PMID: 17562006 DOI: 10.1186/1477-7525-5-32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Winter JW, Heading RC. The nonerosive reflux disease-gastroesophageal reflux disease controversy. Curr Opin Gastroenterol 2008;24:509-15. [PMID: 18622168 DOI: 10.1097/MOG.0b013e3283025c57] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol 2006; 12(5): 747-754 [PMID: 16521188 DOI: 10.3748/wjg.v12.i5.747] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
8 Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol 2012;12:18. [PMID: 22361121 DOI: 10.1186/1471-230X-12-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Huang L, Xu AM, Li TJ, Han WX, Xu J. Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients? World J Gastroenterol 2014; 20(22): 6981-6988 [PMID: 24944492 DOI: 10.3748/wjg.v20.i22.6981] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
10 Orlando RC, Liu S, Illueca M. Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease. Clin Exp Gastroenterol 2010;3:117-25. [PMID: 21694855 DOI: 10.2147/CEG.S12333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
11 Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860. [PMID: 18474247 DOI: 10.1053/j.gastro.2008.05.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 222] [Article Influence: 19.2] [Reference Citation Analysis]
12 Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol. 2008;103:267-275. [PMID: 18289194 DOI: 10.1111/j.1572-0241.2007.01659.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
13 Hunt RH, Yuan Y, Yaghoobi M. GERD: New Strategies and New Failures. Journal of Clinical Gastroenterology 2007;41:S72-80. [DOI: 10.1097/mcg.0b013e31803238d6] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
14 Domínguez-Muñoz JE, Sobrino M. Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease. Drugs 2005;65 Suppl 1:43-50. [PMID: 16335857 DOI: 10.2165/00003495-200565001-00007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Tang RS, Wu JC. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging 2013;8:1433-43. [PMID: 24187492 DOI: 10.2147/CIA.S41350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
16 Vachhani R, Olds G, Velanovich V. Esomeprazole: a proton pump inhibitor. Expert Review of Gastroenterology & Hepatology 2014;3:15-27. [DOI: 10.1586/17474124.3.1.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Hunt RH, Tytgat GH, Malfertheiner P, Fock KM, Heading RC, Katelaris PH, McCarthy DM, McColl KE, Moss SF, Sachs G, Sontag SJ, Thomson AB, Modlin IM. Whistler summary: "the slow rate of rapid progress". J Clin Gastroenterol 2007;41:539-45. [PMID: 17577108 DOI: 10.1097/MCG.0b013e31803d0fd8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
18 Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8-22. [PMID: 18171339 DOI: 10.1111/j.1440-1746.2007.05249.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 8.1] [Reference Citation Analysis]
19 Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-757, e350. [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
20 Junghard O, Wiklund I. Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease. Value in Health 2008;11:765-70. [DOI: 10.1111/j.1524-4733.2007.00313.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
21 Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100:1949-1956. [PMID: 16128938 DOI: 10.1111/j.1572-0241.2005.41956.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
22 van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, Gasco A. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol 2006;101:2096-106. [PMID: 16817845 DOI: 10.1111/j.1572-0241.2006.00751.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
23 Mckeage K, Blick SKA, Croxtall JD, Lyseng-williamson KA, Keating GM. Esomeprazole: A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults. Drugs 2008;68:1571-607. [DOI: 10.2165/00003495-200868110-00009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
24 Miner PB. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux. Aliment Pharmacol Ther. 2006;23:25-32. [PMID: 16483267 DOI: 10.1111/j.1365-2036.2006.02802.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
25 Cohen H, Moraes-Filho JP, Cafferata ML, Tomasso G, Salis G, González O, Valenzuela J, Sharma P, Malfertheiner P, Armstrong D, Lundell L, Corti R, Sakai P, Ceconello I; Latin-American GORD Consensus Group. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2006;18:349-68. [PMID: 16538106 DOI: 10.1097/00042737-200604000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Asghar W, Pittman E, Jamali F. Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch. Daru 2015;23:50. [PMID: 26573220 DOI: 10.1186/s40199-015-0133-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
27 Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009;5:1113-1124. [PMID: 19606942 DOI: 10.1517/17425250903124363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
28 Johnston BT. Oesophageal dysphagia: a stepwise approach to diagnosis and management. Lancet Gastroenterol Hepatol 2017;2:604-9. [PMID: 28691686 DOI: 10.1016/S2468-1253(17)30001-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
29 Lundell L. Therapy of gastroesophageal reflux: evidence-based approach to antireflux surgery. Dig Dis. 2007;25:188-196. [PMID: 17827938 DOI: 10.1159/000103883] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
30 Takahashi M, Katayama Y. Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2-receptor antagonist: Reversal of the tolerance phenomenon. Journal of Gastroenterology and Hepatology 2010;25:1493-7. [DOI: 10.1111/j.1440-1746.2010.06308.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, Satoh H, Nakagawa K, Kobayashi K, Tominaga K. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21 Suppl 2:10-18. [PMID: 15943841 DOI: 10.1111/j.1365-2036.2005.02468.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
32 Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31:627-36. [PMID: 18558796 DOI: 10.2165/00002018-200831070-00008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
33 Chiu C, Hsu C, Wang C, Chang J, Sung C, Lin C, Chen L, Su M, Chen T. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther 2013;38:1054-64. [DOI: 10.1111/apt.12482] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
34 Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther 2011;28:367-88. [PMID: 21484335 DOI: 10.1007/s12325-011-0013-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 McRorie JW Jr, Gibb RD, Miner PB Jr. Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. J Am Assoc Nurse Pract 2014;26:330-9. [PMID: 24825071 DOI: 10.1002/2327-6924.12133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Fry LC, Mönkemüller K, Malfertheiner P. Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—A debate: Con. Curr GERD Rep 2007;1:267-72. [DOI: 10.1007/s12171-007-0027-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Talley NJ. Review article: gastro-oesophageal reflux disease -- how wide is its span? Aliment Pharmacol Ther. 2004;20 Suppl 5:27-37; discussion 38-9. [PMID: 15456461 DOI: 10.1111/j.1365-2036.2004.02134.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
38 Teng M, Khoo AL, Zhao YJ, Lin L, Lim BP, Wu TS, Dan YY. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. J Clin Pharm Ther 2015;40:368-75. [PMID: 25893507 DOI: 10.1111/jcpt.12277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol 2005; 11(28): 4291-4299 [PMID: 16038023 DOI: 10.3748/wjg.v11.i28.4291] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
40 Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584-589. [PMID: 25000345 DOI: 10.1097/MCG.0000000000000125] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
41 Boarino V, Raguzzi I, Marocchi M, Merighi A. Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: an exploratory, post-market, open-label study. Turk J Gastroenterol 2020;31:466-73. [PMID: 32721918 DOI: 10.5152/tjg.2020.19327] [Reference Citation Analysis]
42 Fry LC, Mönkemüller K, Malfertheiner P. Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—A debate: Con. Curr Treat Options Gastro 2007;10:305-11. [DOI: 10.1007/s11938-007-0073-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Koop H. Medical Therapy of Gastro-Oesophageal Reflux Disease. In: Granderath FA, Kamolz T, Pointner R, editors. Gastroesophageal Reflux Disease. Vienna: Springer-Verlag; 2006. pp. 103-11. [DOI: 10.1007/3-211-32317-1_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Morgner-Miehlke A, Petersen K, Miehlke S, Labenz J. Esomeprazole: potent acid suppression in the treatment of acid-related disorders. Expert Rev Clin Immunol 2005;1:511-27. [PMID: 20477595 DOI: 10.1586/1744666X.1.4.511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635-643. [PMID: 22860764 DOI: 10.1111/apt.12007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
46 Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905-921. [PMID: 21126703 DOI: 10.1016/j.bpg.2010.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
47 Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol. 2009;24:1326-1332. [PMID: 19702900 DOI: 10.1111/j.1440-1746.2009.05879.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
48 Rydén A, Martin M, Halling K, Niklasson A. Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study. Patient. 2013;6:307-314. [PMID: 23990378 DOI: 10.1007/s40271-013-0024-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006;41:1147-54. [PMID: 16990199 DOI: 10.1080/00365520600741546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
50 Miehlke S, Löbe S, Madisch A, Kuhlisch E, Laass M, Grossmann D, Knoth H, Morgner A, Labenz J. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharmacol Ther 2011;33:471-6. [PMID: 21175704 DOI: 10.1111/j.1365-2036.2010.04544.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
51 Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G; ON BEHALF OF THE TREAT STUDY GROUP. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Alimentary Pharmacology & Therapeutics 2009;29:967-78. [DOI: 10.1111/j.1365-2036.2009.03948.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
52 Petryszyn P, Staniak A, Grzegrzolka J. Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland? J Comp Eff Res 2016;5:169-78. [PMID: 26946951 DOI: 10.2217/cer.15.63] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Kusano M, Hosaka H, Kawamura O, Kawada A, Kuribayashi S, Shimoyama Y, Yasuoka H, Mizuide M, Tomizawa T, Sagawa T, Sato K, Yamada M. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. J Gastroenterol 2015;50:298-304. [PMID: 24919745 DOI: 10.1007/s00535-014-0972-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Junghard O, Wiklund IK. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease: . European Journal of Gastroenterology & Hepatology 2007;19:555-60. [DOI: 10.1097/meg.0b013e328133f2d1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]